In my lab, we are interested in the development and healthy maintenance of blood vessels. Certain diseases require blood vessel development for their progression; tumors, for example, thrive on blood flow. In those situations, we want to know how to stop or reverse vessel growth in order to halt disease progression. At other times, such as when wounds are healing, vessel growth is necessary and positive. In those cases, we want to learn how to build new vessels.
Blood vessel development is similar in mice and humans, so we use mice to study and manipulate vessels. By altering one or two genes at a time in mice, we can begin to understand how those genes contribute to blood vessel development and maintenance. We ultimately hope to identify genes that are critical for building and protecting healthy blood vessels, since those genes would be important therapeutic targets for controlling the growth and upkeep of blood vessels in our bodies.
Watch Dr. Griffin’s 2012 TEDxOU Lecture: Epigenetics and the Influence of Our Genes
My lab studies the transcriptional regulation of genes that impact blood and lymphatic vascular development and maintenance. I became interested in vascular biology and development during my graduate training with Shaun Coughlin at UCSF and in epigenetics and transcription during my postdoctoral training with Terry Magnuson at UNC-Chapel Hill. When I launched my independent career in the Cardiovascular Biology Research Program at OMRF in 2008, I combined these interests together and initiated a program studying the impact of ATP-dependent chromatin-remodeling complexes on vascular development. These complexes transiently modulate chromatin to facilitate transcriptional regulation of target genes. By generating mice with vascular-specific mutations in these complexes, my lab assesses how chromatin remodeling influences expression of genes that affect endothelial cell morphology and behavior. Our long-term goal is to generate insights that can be exploited for developing therapeutic approaches to combat vascular pathologies.
For more details about our current research, please see my lab website: https://griffinc.omrf.org/
B.A., Harvard University, Cambridge, MA, 1995
Ph.D., University of California, San Francisco, CA, 2001
Postdoc, University of North Carolina at Chapel Hill, 2001-2008
Honors and Awards
1995 Magna cum laude with highest honors in Biology, Harvard College
2006-2011 NIH Pathway to Independence Award (NHLBI)
2013 J. Donald and Patricia Capra Award for Scientific Achievement (OMRF)
2019 Edward L. & Thelma Gaylord Prize for Scientific Excellence (OMRF)
2019-2026 NIH Emerging Investigator Award (NHLBI)
2020 Scott Zarrow Chair in Biomedical Research (OMRF)
2009-present Peer Reviewer for American Heart Association
2015-2018 Councilor for North American Vascular Biology Organization
2016-2019 National Research Funding Subcommittee for American Heart Association
2016-2022 Central Oklahoma Board of Directors (President 2018-2020) for American Heart Association
2016-present Editorial Board Member for Angiogenesis
2017-present Founder and Chair of OMRF Postdoctoral Training Committee
2019-2023 Standing Member of NIH Cardiovascular Differentiation and Development study section
2021-2022 President of North American Vascular Biology Organization
North American Vascular Biology Organization (since 2006)
American Heart Association (since 2014)
Society for Developmental Biology (since 2015)
Joined OMRF Scientific Staff in 2008
Lin PK, Salvador J, Xie J, Aguera KN, Koller GM, Kemp SS, Griffin CT, Davis GE. Selective and marked blockade of endothelial sprouting behavior using paclitaxel and related pharmacologic agents. Am J Pathol, 2021 September, PMID: 34563512
Gao S, Menendez M, Kurylowicz K, Griffin CT. Genomic locus proteomic screening identifies the NF-κB signaling pathway components NFκB1 and IKBKG as transcriptional regulators of Ripk3 in endothelial cells. PLoS One 16:e0253519, 2021 June, PMID: 34153072, PMCID: PMC8216549
Colijn S, Gao S, Ingram KG, Menendez M, Muthukumar V, Silasi-Mansat R, Chmielewska JJ, Hinsdale M, Lupu F, Griffin CT. The NuRD chromatin-remodeling complex enzyme CHD4 prevents hypoxia-induced endothelial Ripk3 transcription and murine embryonic vascular rupture. Cell Death Differ. 2020 Feb;27(2):618-631. PMID: 31235857, PMCID: PMC7206092
Gao S, Silasi-Mansat R, Behar AR, Lupu F, Griffin CT. Excessive Plasmin Compromises Hepatic Sinusoidal Vascular Integrity After Acetaminophen Overdose. Hepatology. 2018 Nov;68(5):1991-2003. PMID: 29729197, PMCID: PMC6204085
Menendez MT, Ong EC, Shepherd BT, Muthukumar V, Silasi-Mansat R, Lupu F, Griffin CT. BRG1 (Brahma-Related Gene 1) Promotes Endothelial Mrtf Transcription to Establish Embryonic Capillary Integrity. Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1674-1682. PMID: 28729363, PMCID: PMC5570645
Crosswhite PL, Podsiadlowska JJ, Curtis CD, Gao S, Xia L, Srinivasan RS, Griffin CT. CHD4-regulated plasmin activation impacts lymphovenous hemostasis and hepatic vascular integrity. J Clin Invest. 2016; 126: 2254-2266. PMID: 27140400, PMCID: PMC4887170
Ingram KG, Curtis CD, Silasi-Mansat R, Lupu F, Griffin CT. The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 2013; 9: e1004031. PMID: 24348274, PMCID: PMC3861115
Davis RB, Curtis CD, Griffin CT. BRG1 promotes COUP-TFII expression and venous specification during embryonic vascular development. Development. 2013; 140: 1272-1281. PMID: 23406903, PMCID: PMC3585661
Matthew Menendez, Ph.D.
Senior Postdoctoral Fellow
Chris Schafer, Ph.D.
Research Assistant Member
Charmain Fernando, Ph.D.
Senior Postdoctoral Fellow
Jun Xie, M.D.
Administrative Assistant II
News from the Griffin lab
The National Institutes of Health awarded grants worth more than $4 million to two OMRF scientists. Patrick Gaffney, M.D., and Courtney Griffin, Ph.D., were each awarded five-year R01 grants to research genes related to lupus and vascular development, respectively. After identifying two genes associated with lupus—a chronic autoimmune disease that affects an estimated 2 million […]
A new wave of researchers has joined the Oklahoma Medical Research Foundation’s scientific staff as part of the foundation’s expansion. OMRF has added seven new scientists to its staff. In addition, two research assistants have been promoted to faculty-level positions. The new researchers have come to OMRF from a variety of institutions across the U.S. […]